Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;33(1):49-59.
doi: 10.1007/s40273-014-0211-5.

Concepts of 'personalization' in personalized medicine: implications for economic evaluation

Wolf Rogowski  1 , Katherine Payne, Petra Schnell-Inderst, Andrea Manca, Ursula Rochau, Beate Jahn, Oguzhan Alagoz, Reiner Leidl, Uwe Siebert
Affiliations

Concepts of 'personalization' in personalized medicine: implications for economic evaluation

Wolf Rogowski et al. Pharmacoeconomics. 2015 Jan.

Abstract

Context: This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required.

Methods: A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nominal group technique. Workshop findings were recorded using extensive note taking, and summarized using thematic data analysis. The workshop was complemented by structured literature searches.

Results: The key finding emerging from the workshop, using an economic perspective, was that two distinct, but linked, interpretations of the concept of PM exist (personalization by 'physiology' or 'preferences'). These interpretations involve specific challenges for the design and conduct of economic evaluations. Existing evaluative (extra-welfarist) frameworks were generally considered appropriate for evaluating PM. When 'personalization' is viewed as using physiological biomarkers, challenges include representing complex care pathways; representing spillover effects; meeting data requirements such as evidence on heterogeneity; and choosing appropriate time horizons for the value of further research in uncertainty analysis. When viewed as tailoring medicine to patient preferences, further work is needed regarding revealed preferences, e.g. treatment (non)adherence; stated preferences, e.g. risk interpretation and attitude; consideration of heterogeneity in preferences; and the appropriate framework (welfarism vs. extra-welfarism) to incorporate non-health benefits.

Conclusions: Ideally, economic evaluations should take account of both interpretations of PM and consider physiology and preferences. It is important for decision makers to be cognizant of the issues involved with the economic evaluation of PM to appropriately interpret the evidence and target future research funding.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Structured overview of methodological issues in the economic evaluation of personalizedmedicine
See this image and copyright information in PMC

References

    1. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55. - PMC - PubMed
    1. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012 Dec;15(8):1162–71. - PubMed
    1. Berger AC, Olson S. The Economics of Genomic Medicine - Workshop Summary. Washington, DC: The National Academies Press; 2013. - PubMed
    1. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009 Jul;10(7):489–95. - PubMed
    1. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013 Sep-Oct;16(6 Suppl):S20–6. - PubMed

Publication types